cabozantinib

Cabozantinib is used in two forms. A capsule form is used since 2012 to treat medullary thyroid cancer and a tablet form is used since 2016 as a second line treatment for renal cell carcinoma.. Reference standards of Cabozantinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

No Data Found